NCT05382377

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-025 CAR-T Therapy in Advanced NKG2DL+ Solid Tumors

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: jianming xu · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D-based CAR-T cells infusion in the treatment of advanced NKG2DL+ solid tumors.

Detailed description

This is an open-label, dose escalation/expansion study to assess the safety, tolerability, and efficacy of KD-025 cell infusion in patients with advanced NKG2DL+ solid tumors. In this study, the enrollment of the patients must meet the inclusion and exclusion criteria. All subjects will be undergo screening, pre-treatment (cell product preparation, lymphodepleting chemotherapy), treatment and follow up.

Conditions

• CRC
• Solid Tumor

Interventions

Type	Name	Description
BIOLOGICAL	KD-025	Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Timeline

• Start date: 2022-05-17
• Primary completion: 2024-05-17
• Completion: 2026-05-17
• First posted: 2022-05-19
• Last updated: 2022-05-19

Locations

1 site across 1 country: China